Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Zhiyu Liu, Zijun Y. Xu-Monette, Xin Cao, Ganiraju C. Manyam, Xiaoxiao Wang, Alexandar Tzankov, Yi Xia, Xin Li, Carlo Visco, Ruifang Sun, Li Zhang, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W L Choi & 11 others J. Han Van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J M Ferreri, Ben M. Parsons, Michael B. Møller, Miguel A. Piris, Jane N. Winter, Dennis P. O'Malley, L. Jeffrey Medeiros, Ken H. Young

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58%) had survivin overexpression with a cutoff of >25%, associated with an International Prognostic Index score of >2 (P=0.015), disease in ≥2 extranodal sites (P=0.011), and a high Ki-67 index (P

Original languageEnglish
Pages (from-to)1297-1314
Number of pages18
JournalModern Pathology
Volume28
Issue number10
DOIs
Publication statusPublished - Oct 3 2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Inhibitor of Apoptosis Proteins
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Therapeutics
Immunohistochemistry
Rituximab
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. / Liu, Zhiyu; Xu-Monette, Zijun Y.; Cao, Xin; Manyam, Ganiraju C.; Wang, Xiaoxiao; Tzankov, Alexandar; Xia, Yi; Li, Xin; Visco, Carlo; Sun, Ruifang; Zhang, Li; Montes-Moreno, Santiago; Dybkær, Karen; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L.; Hsi, Eric D.; Choi, William W L; Van Krieken, J. Han; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andrés J M; Parsons, Ben M.; Møller, Michael B.; Piris, Miguel A.; Winter, Jane N.; O'Malley, Dennis P.; Medeiros, L. Jeffrey; Young, Ken H.

In: Modern Pathology, Vol. 28, No. 10, 03.10.2015, p. 1297-1314.

Research output: Contribution to journalArticle

Liu, Z, Xu-Monette, ZY, Cao, X, Manyam, GC, Wang, X, Tzankov, A, Xia, Y, Li, X, Visco, C, Sun, R, Zhang, L, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, O'Malley, DP, Medeiros, LJ & Young, KH 2015, 'Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy', Modern Pathology, vol. 28, no. 10, pp. 1297-1314. https://doi.org/10.1038/modpathol.2015.94
Liu, Zhiyu ; Xu-Monette, Zijun Y. ; Cao, Xin ; Manyam, Ganiraju C. ; Wang, Xiaoxiao ; Tzankov, Alexandar ; Xia, Yi ; Li, Xin ; Visco, Carlo ; Sun, Ruifang ; Zhang, Li ; Montes-Moreno, Santiago ; Dybkær, Karen ; Chiu, April ; Orazi, Attilio ; Zu, Youli ; Bhagat, Govind ; Richards, Kristy L. ; Hsi, Eric D. ; Choi, William W L ; Van Krieken, J. Han ; Huh, Jooryung ; Ponzoni, Maurilio ; Ferreri, Andrés J M ; Parsons, Ben M. ; Møller, Michael B. ; Piris, Miguel A. ; Winter, Jane N. ; O'Malley, Dennis P. ; Medeiros, L. Jeffrey ; Young, Ken H. / Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. In: Modern Pathology. 2015 ; Vol. 28, No. 10. pp. 1297-1314.
@article{3c61e471fe474040806b03db2e3b8963,
title = "Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy",
abstract = "Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58{\%}) had survivin overexpression with a cutoff of >25{\%}, associated with an International Prognostic Index score of >2 (P=0.015), disease in ≥2 extranodal sites (P=0.011), and a high Ki-67 index (P",
author = "Zhiyu Liu and Xu-Monette, {Zijun Y.} and Xin Cao and Manyam, {Ganiraju C.} and Xiaoxiao Wang and Alexandar Tzankov and Yi Xia and Xin Li and Carlo Visco and Ruifang Sun and Li Zhang and Santiago Montes-Moreno and Karen Dybk{\ae}r and April Chiu and Attilio Orazi and Youli Zu and Govind Bhagat and Richards, {Kristy L.} and Hsi, {Eric D.} and Choi, {William W L} and {Van Krieken}, {J. Han} and Jooryung Huh and Maurilio Ponzoni and Ferreri, {Andr{\'e}s J M} and Parsons, {Ben M.} and M{\o}ller, {Michael B.} and Piris, {Miguel A.} and Winter, {Jane N.} and O'Malley, {Dennis P.} and Medeiros, {L. Jeffrey} and Young, {Ken H.}",
year = "2015",
month = "10",
day = "3",
doi = "10.1038/modpathol.2015.94",
language = "English",
volume = "28",
pages = "1297--1314",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

AU - Liu, Zhiyu

AU - Xu-Monette, Zijun Y.

AU - Cao, Xin

AU - Manyam, Ganiraju C.

AU - Wang, Xiaoxiao

AU - Tzankov, Alexandar

AU - Xia, Yi

AU - Li, Xin

AU - Visco, Carlo

AU - Sun, Ruifang

AU - Zhang, Li

AU - Montes-Moreno, Santiago

AU - Dybkær, Karen

AU - Chiu, April

AU - Orazi, Attilio

AU - Zu, Youli

AU - Bhagat, Govind

AU - Richards, Kristy L.

AU - Hsi, Eric D.

AU - Choi, William W L

AU - Van Krieken, J. Han

AU - Huh, Jooryung

AU - Ponzoni, Maurilio

AU - Ferreri, Andrés J M

AU - Parsons, Ben M.

AU - Møller, Michael B.

AU - Piris, Miguel A.

AU - Winter, Jane N.

AU - O'Malley, Dennis P.

AU - Medeiros, L. Jeffrey

AU - Young, Ken H.

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58%) had survivin overexpression with a cutoff of >25%, associated with an International Prognostic Index score of >2 (P=0.015), disease in ≥2 extranodal sites (P=0.011), and a high Ki-67 index (P

AB - Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58%) had survivin overexpression with a cutoff of >25%, associated with an International Prognostic Index score of >2 (P=0.015), disease in ≥2 extranodal sites (P=0.011), and a high Ki-67 index (P

UR - http://www.scopus.com/inward/record.url?scp=84942987649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942987649&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2015.94

DO - 10.1038/modpathol.2015.94

M3 - Article

VL - 28

SP - 1297

EP - 1314

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 10

ER -